Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Cozzi

Showing results (231-240 of 256) with videos related to

Pageof 26
Sort By:
International Journal of Antimicrobial Agents|September 12, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?A Vergori, R Gagliardini, N Gianotti, et al.
HIV Medicine|May 31, 2018
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparisonL Taramasso, A Di Biagio, F Maggiolo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 20, 2010
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort studyM C F Prosperi, A Cozzi-Lepri, A Castagna, et al.
HIV Medicine|November 22, 2018
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014A d'Arminio Monforte, H Diaz-Cuervo, A De Luca, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 4, 2013
The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infectionC da Cunha-Bang, N Kirkby, M Sønderholm, et al.
Infection|August 12, 2009
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological featuresG Morsica, F Ancarani, S Bagaglio, et al.
Journal of Biological Regulators and Homeostatic Agents|August 5, 2020
Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patientsE M Lori, A Cozzi-Lepri, A Tavelli, et al.
AIDS Care|May 17, 2022
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sexA Cingolani, A Tavelli, G V Calvino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcomaFrancesca Diomedi-Camassei, Heather P McDowell, Maria A De Ioris, et al.
AIDS (London, England)|June 16, 2001
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA studyA Cozzi Lepri, A N Phillips, A d'Arminio Monforte, et al.
Pageof 26

Showing results (231-240 of 256) with videos related to

Sort By:
Pageof 26
International Journal of Antimicrobial Agents|September 12, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?A Vergori, R Gagliardini, N Gianotti, et al.
HIV Medicine|May 31, 2018
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparisonL Taramasso, A Di Biagio, F Maggiolo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 20, 2010
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort studyM C F Prosperi, A Cozzi-Lepri, A Castagna, et al.
HIV Medicine|November 22, 2018
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014A d'Arminio Monforte, H Diaz-Cuervo, A De Luca, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 4, 2013
The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infectionC da Cunha-Bang, N Kirkby, M Sønderholm, et al.
Infection|August 12, 2009
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological featuresG Morsica, F Ancarani, S Bagaglio, et al.
Journal of Biological Regulators and Homeostatic Agents|August 5, 2020
Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patientsE M Lori, A Cozzi-Lepri, A Tavelli, et al.
AIDS Care|May 17, 2022
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sexA Cingolani, A Tavelli, G V Calvino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcomaFrancesca Diomedi-Camassei, Heather P McDowell, Maria A De Ioris, et al.
AIDS (London, England)|June 16, 2001
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA studyA Cozzi Lepri, A N Phillips, A d'Arminio Monforte, et al.
Pageof 26